Shenzhen Kangtai Biological Products Co., Ltd.

SZSE:300601 Stock Report

Market Cap: CN¥16.1b

Shenzhen Kangtai Biological Products Balance Sheet Health

Financial Health criteria checks 5/6

Shenzhen Kangtai Biological Products has a total shareholder equity of CN¥9.7B and total debt of CN¥2.1B, which brings its debt-to-equity ratio to 21.8%. Its total assets and total liabilities are CN¥14.5B and CN¥4.8B respectively. Shenzhen Kangtai Biological Products's EBIT is CN¥370.1M making its interest coverage ratio 20.9. It has cash and short-term investments of CN¥310.7M.

Key information

21.8%

Debt to equity ratio

CN¥2.12b

Debt

Interest coverage ratio20.9x
CashCN¥310.71m
EquityCN¥9.71b
Total liabilitiesCN¥4.81b
Total assetsCN¥14.52b

Recent financial health updates

Here's Why Shenzhen Kangtai Biological Products (SZSE:300601) Has A Meaningful Debt Burden

Sep 25
Here's Why Shenzhen Kangtai Biological Products (SZSE:300601) Has A Meaningful Debt Burden

Shenzhen Kangtai Biological Products (SZSE:300601) Seems To Use Debt Quite Sensibly

May 25
Shenzhen Kangtai Biological Products (SZSE:300601) Seems To Use Debt Quite Sensibly

Recent updates

Market Cool On Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Earnings

Jan 17
Market Cool On Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Earnings

Investors Appear Satisfied With Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Prospects As Shares Rocket 32%

Oct 13
Investors Appear Satisfied With Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Prospects As Shares Rocket 32%

Here's Why Shenzhen Kangtai Biological Products (SZSE:300601) Has A Meaningful Debt Burden

Sep 25
Here's Why Shenzhen Kangtai Biological Products (SZSE:300601) Has A Meaningful Debt Burden

These Analysts Just Made A Massive Downgrade To Their Shenzhen Kangtai Biological Products Co., Ltd. (SZSE:300601) EPS Forecasts

Sep 02
These Analysts Just Made A Massive Downgrade To Their Shenzhen Kangtai Biological Products Co., Ltd. (SZSE:300601) EPS Forecasts

Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Share Price Not Quite Adding Up

Aug 13
Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Share Price Not Quite Adding Up

Shenzhen Kangtai Biological Products (SZSE:300601) Seems To Use Debt Quite Sensibly

May 25
Shenzhen Kangtai Biological Products (SZSE:300601) Seems To Use Debt Quite Sensibly

Shenzhen Kangtai Biological Products' (SZSE:300601) Promising Earnings May Rest On Soft Foundations

May 03
Shenzhen Kangtai Biological Products' (SZSE:300601) Promising Earnings May Rest On Soft Foundations

Earnings Report: Shenzhen Kangtai Biological Products Co., Ltd. Missed Revenue Estimates By 49%

May 01
Earnings Report: Shenzhen Kangtai Biological Products Co., Ltd. Missed Revenue Estimates By 49%

Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Share Price Matching Investor Opinion

Feb 27
Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Share Price Matching Investor Opinion

Financial Position Analysis

Short Term Liabilities: 300601's short term assets (CN¥5.9B) exceed its short term liabilities (CN¥2.6B).

Long Term Liabilities: 300601's short term assets (CN¥5.9B) exceed its long term liabilities (CN¥2.2B).

Debt to Equity History and Analysis

Debt Level: 300601's net debt to equity ratio (18.6%) is considered satisfactory.

Reducing Debt: 300601's debt to equity ratio has increased from 10.7% to 21.8% over the past 5 years.

Debt Coverage: 300601's debt is well covered by operating cash flow (30.4%).

Interest Coverage: 300601's interest payments on its debt are well covered by EBIT (20.9x coverage).

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 18:33
End of Day Share Price 2025/01/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shenzhen Kangtai Biological Products Co., Ltd. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pei ChengChina Galaxy Securities Co., Ltd.
Diandian LiChina Merchants Securities Co. Ltd.
Bing ZhaoChina Renaissance Securities